Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 533 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Pregnant Mom Had to Fight for a Diagnosis After Finding a... August 2, 2021 Learning the lessons of COVID-19: Protecting cancer services and research through... November 9, 2020 EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC October 6, 2020 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Load more HOT NEWS An Oncology Hospital at Home Model of Acute Care Shows Promise Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC...
